How John Kerry voted on all votes |
Member |
Most
DEMS |
Most
REPS |
|---|---|---|---|
Defeated VOTE 113S. 2343; A bill to amend the Higher Education Act of 1965 to extend the reduced interest rate for Federal Direct Stafford Loans, and for other purposes. |
|||
Rejected VOTE 112Alexander Amdt. No. 2153; In the nature of a substitute. |
|||
Passed VOTE 111S. 3187 As Amended; A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes. |
|||
Agreed to VOTE 110Motion to Table Durbin Amdt. No. 2127; To require manufacturers of dietary supplements to register dietary supplement products with the Food and Drug Administration. |
|||
Rejected VOTE 109Sanders Amdt. No. 2109; To revoke the exclusivity of certain entities that are responsible for violations of the Federal Food, Drug, and Cosmetic Act, the False Claims Act, and other certain laws. |
|||
Rejected VOTE 108McCain Amdt. No. 2107; To allow the importation by individuals of safe and affordable drugs from Canada. |
|||
Agreed to VOTE 107Motion to Table Paul Amdt. No. 2143; To amend the Federal Food, Drug, and Cosmetic Act concerning claims about the effects of foods and dietary supplements on health-related conditions and disease, to prohibit employees of the Food and Drug Administration from carrying firearms and making arrests without warrants, and to adjust the mens rea of certain prohibited acts under the Federal Food, Drug, and Cosmetic Act to knowing and willful. |
|||
Rejected VOTE 106Murkowski Amdt. No. 2108; To prohibit approval by the Food and Drug Administration of genetically engineered fish unless the National Oceanic and Atmospheric Administration concurs with such approval. |
|||
Rejected VOTE 105Bingaman Amdt. No. 2111; To provide substantial savings in health care costs to the Federal government and consumers by fostering competition among generic pharmaceutical manufacturers and ensuring that anti-competitive "pay-for-delay" settlements between brand-name and generic pharmaceutical manufacturers do not block generic drugs from entering the market. |
|||
Confirmed VOTE 104Confirmation Paul J. Watford, of California, to be United States Circuit Judge for the Ninth Circuit |
